Imperial College London
Dr Nina Moderau

DrNinaModerau

Faculty of Medicine, Department of Surgery & Cancer

Research Associate
 
 
 
//

Contact

 

+44 (0)20 7594 2822n.moderau

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Alifrangis:2018:10.18632/oncotarget.24375,
author = {Alifrangis, C and Carter, P and Cereser, B and Chandrasinghe, P and Belluz, LDB and Lim, E and Moderau, N and Poyia, F and Tabassum, N and Zhang, H and Krell, J and Stebbing, J},
doi = {10.18632/oncotarget.24375},
journal = {Oncotarget},
pages = {12805--12811},
title = {Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments.},
url = {http://dx.doi.org/10.18632/oncotarget.24375},
volume = {9},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - In this study we utilized data on patient responses to guided treatments, and we evaluated their benefit for a non-small cell lung cancer cohort. The recommended therapies used were predicted using tumor molecular profiles that involved a range of biomarkers but primarily used immunohistochemistry markers. A dataset describing 91 lung non-small cell lung cancer patients was retrospectively split into two. The first group's drugs were consistent with a treatment plan whereby all drugs received agreed with their tumor's molecular profile. The second group each received one or more drug that was expected to lack benefit. We found that there was no significant difference in overall survival or mortality between the two groups. Patients whose treatments were predicted to be of benefit survived for an average of 402 days, compared to 382 days for those that did not (P = 0.7934). In the matched treatment group, 48% of patients were deceased by the time monitoring had finished compared to 53% in the unmatched group (P = 0.6094). The immunohistochemistry biomarker for the ERCC1 receptor was found to be a marker that could be used to predict future survival; ERCC1 loss was found to be predictive of poor survival.
AU  - Alifrangis,C
AU  - Carter,P
AU  - Cereser,B
AU  - Chandrasinghe,P
AU  - Belluz,LDB
AU  - Lim,E
AU  - Moderau,N
AU  - Poyia,F
AU  - Tabassum,N
AU  - Zhang,H
AU  - Krell,J
AU  - Stebbing,J
DO  - 10.18632/oncotarget.24375
EP  - 12811
PY  - 2018///
SN  - 1949-2553
SP  - 12805
TI  - Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments.
T2  - Oncotarget
UR  - http://dx.doi.org/10.18632/oncotarget.24375
UR  - https://www.ncbi.nlm.nih.gov/pubmed/29560111
UR  - http://hdl.handle.net/10044/1/59368
VL  - 9
ER  -
Download